FDA Drug Recalls

775 recalls, newest first

Feb 7, 2023 Class II · Moderate risk

Pravastatin Sodium Tablets USP 20 mg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-009-15 D-0422-2023

Feb 7, 2023 Class II · Moderate risk

Pravastatin Sodium Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-008-15 D-0421-2023

Feb 7, 2023 Class II · Moderate risk

Pirfenidone Tablets 801 mg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-468-15 D-0420-2023

Feb 7, 2023 Class II · Moderate risk

Pirfenidone Tablets 267 mg 90-count bottle x3/Carton

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-467-15 D-0419-2023

Feb 7, 2023 Class II · Moderate risk

Vigabatrin for Oral Solution

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-521-63 D-0418-2023

Feb 7, 2023 Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-372-10 D-0417-2023

Feb 7, 2023 Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-371-10 D-0416-2023

Feb 7, 2023 Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-370-10 D-0415-2023

Feb 7, 2023 Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-369-10 D-0414-2023

Feb 7, 2023 Class II · Moderate risk

Succinylcholine Chloride Injection

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-493-03 D-0413-2023

Feb 7, 2023 Class II · Moderate risk

Simvastatin Tablets USP 80 mg Rx Only

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-007-15 D-0412-2023

Feb 7, 2023 Class II · Moderate risk

Simvastatin Tablets USP 40 mg Rx Only

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-006-15 D-0411-2023

Feb 7, 2023 Class II · Moderate risk

Simvastatin Tablets USP 20 mg Rx Only

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-005-15 D-0410-2023

Feb 7, 2023 Class II · Moderate risk

Simvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-004-15 D-0409-2023

Feb 7, 2023 Class II · Moderate risk

Simvastatin Tablets USP 5 mg Rx Only

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-156-15 D-0408-2023

Feb 7, 2023 Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-287-10 D-0407-2023

Feb 7, 2023 Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-286-15 D-0406-2023

Feb 7, 2023 Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-285-15 D-0405-2023

Feb 7, 2023 Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-284-15 D-0404-2023

Feb 7, 2023 Class II · Moderate risk

Phenylephrine Hydrochloride Injection

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-466-03 D-0403-2023

Feb 7, 2023 Class II · Moderate risk

Phenylephrine Hydrochloride Injection

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-465-31 D-0402-2023

Feb 7, 2023 Class II · Moderate risk

Phenylephrine Hydrochloride Injection

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-464-63 D-0401-2023

Feb 7, 2023 Class II · Moderate risk

Montelukast Sodium Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-119-10 D-0400-2023

Feb 7, 2023 Class II · Moderate risk

Glycopyrrolate Injection

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-474-05 D-0399-2023

Feb 7, 2023 Class II · Moderate risk

Glycopyrrolate Injection

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-473-31 D-0398-2023

Recalls by year

2026563
2025778
2024557
20231,122
20221,390
20211,152
2020930
20191,788
20181,681
20171,141
20161,199
20151,733
20141,309
20132,085
2012534
201134
20104
20072
20061